Literature DB >> 9671212

Tumor necrosis factor beta and soluble APO-1/Fas independently predict progression to AIDS in HIV-seropositive patients.

F J Medrano1, M Leal, D Arienti, C Rey, A Zagliani, Y Torres, A Sanchez-Quijano, E Lissen, M Clerici.   

Abstract

The relationship between serum concentration of different components of the nerve growth factor/tumor necrosis factor (TNF) receptor family, including soluble APO-1/Fas (sAPO-1/Fas) and progression of HIV infection, was analyzed in a case-control study of individuals selected from a cohort of HIV-seropositive patients who were progressing or not progressing to AIDS while being treated with nucleoside analogs. HIV-seronegative healthy controls were also analyzed. The results showed that, despite close matching for immunologic (CD4 cell count, beta2-microglobulin concentration) and virologic (p24 antigen, detection of HIV syncytium-inducing phenotype, plasma HIV viremia) parameters, the baseline serum concentrations of TNF-beta and sAPO-1/Fas were statistically different between progressing and nonprogressing patients. In addition, serum concentrations of TNF-beta and sAPO-1/Fas showed the strongest independent predictive power for progression to AIDS in a multivariate conditional logistic regression model. Because TNF-beta and Fas were suggested to be mediators of antigen-induced cell death (AICD) in HIV infection and sAPO-1/Fas was hypothesized to protect lymphocyte against AICD, these data suggest an important pathogenetic role for AICD in the progression of HIV infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671212     DOI: 10.1089/aid.1998.14.835

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  3 in total

Review 1.  Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010.

Authors:  James D Neaton; Jacqueline Neuhaus; Sean Emery
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

2.  Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202.

Authors:  Grace A McComsey; Douglas Kitch; Paul E Sax; Camlin Tierney; Nasreen C Jahed; Kathleen Melbourne; Belinda Ha; Todd T Brown; Anthony Bloom; Neal Fedarko; Eric S Daar
Journal:  J Acquir Immune Defic Syndr       Date:  2014-02-01       Impact factor: 3.731

3.  Acquisition of host-derived CD40L by HIV-1 in vivo and its functional consequences in the B-cell compartment.

Authors:  Michaël Imbeault; Michel Ouellet; Katia Giguère; Jonathan Bertin; Dave Bélanger; Geneviève Martin; Michel J Tremblay
Journal:  J Virol       Date:  2010-12-22       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.